13:38:37 EST Sun 16 Feb 2025
Enter Symbol
or Name
USA
CA



Login ID:
Password:
Save

T:APLI - APPILI THERAPEUTICS INC. J - https://www.appilitherapeutics.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
APLI - T  493.00.03·0.035160.00.035+0.00516.780.4390.03  0.035  0.030.06  0.02510:07:1417:5915 min RT 2¢
TSX - T493.00.03·0.035160.00.0341.0130.03  0.03  0.030.06  0.02509:32:4315 min
NEO ATS - U 0.035+0.00516.76.0010.035  0.035  0.03510:07:1415 min
Alpha - A 0.035+0.00516.732.0110.035  0.035  0.03510:07:1415 min
CXD - D 0.030.21    Nov 1315 min
TriAct - M 0.031.23    Sep 11/2015 min

Recent Trades - All 9 today
Time ETExPriceChangeVolumeBuyerSellerMarkers
15:09:57M0.0350.0051007 TD Sec7 TD SecE
15:09:29M0.0350.00530080 National Bank80 National BankE
10:07:14A0.0350.00532,00033 Canaccord1 AnonymousK
10:07:14U0.0350.0056,00033 Canaccord1 AnonymousK
10:07:14M0.0350.00575533 Canaccord2 RBCE
09:32:43T0.03 21,0009 BMO Nesbitt1 AnonymousK
09:32:43T0.03 10,00019 Desjardins1 AnonymousK
09:32:43T0.03 10,00019 Desjardins1 AnonymousKL
09:30:01D0.03 2007 TD Sec7 TD SecE
        

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolPriceTypeHeadline
2025-02-14 17:59C:APLI0.03SEDAR Interim MD & ASEDAR Interim MD & A
2025-02-14 17:53C:APLI0.03SEDAR Interim Financial StatementsSEDAR Interim Financial Statements
2025-02-14 17:06C:APLI0.03News ReleaseAppili Therapeutics Reports Financial and Operational Results for Third Quarter of Fiscal Year 2025
2024-12-12 08:15C:APLI0.035News ReleaseAditxt's Subsidiary Adimune Successfully Completes Preclinical Efficacy and Safety Studies for Its Immune Modulation Therapeutic ADI Platform, Advancing Toward First-in-Human Clinical Trials
2024-11-19 16:31C:APLI0.03News ReleaseAppili receives final court order for Aditxt deal
2024-11-14 08:35C:APLI0.035SEDAR Interim MD & ASEDAR Interim MD & A
2024-11-14 08:29C:APLI0.035SEDAR Interim Financial StatementsSEDAR Interim Financial Statements
2024-11-14 07:15C:APLI0.035News ReleaseAppili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2025
2024-11-08 08:30C:APLI0.04News ReleaseAditxt Provides Update on Equity Line of Credit, ATM Usage, and Outstanding Number of Shares
2024-11-07 08:30C:APLI0.035News ReleaseAditxt's Target Acquisition Appili Therapeutics Announces Results of Special Meeting of Shareholders
2024-11-06 18:20C:APLI0.035News ReleaseAppili shareholders approve Aditxt deal
2024-11-06 08:30C:APLI0.04News ReleaseAditxt Acquisition Target Evofem Biosciences Secures Investor Support Through Voting Agreements for Merger with Aditxt's Subsidiary Adifem
2024-10-31 14:51C:APLI0.035News ReleaseAppili receives feedback from FDA for ATI-1801 plan
2024-10-31 08:30C:APLI0.035News ReleaseAditxt's Target Acquisition Appili Therapeutics Announces Alignment with FDA on Development Requirements for ATI-1801 Topical Antiparasitic Product NDA Submission
2024-10-30 17:35C:APLI0.035News ReleaseAppili Therapeutics to host conference call Nov. 1
2024-10-29 08:15C:APLI0.035News ReleaseSylvia Hermina Joins Aditxt's Board of Directors, Elevating Leadership with Broader Perspectives
2024-10-28 08:15C:APLI0.035News ReleaseAditxt Completes Final Equity Investment and Key Milestone Under the Amended and Restated Merger Agreement with Evofem
2024-10-17 07:15C:APLI0.035News ReleaseAppili Therapeutics Presents Update on ATI-1701 Biodefense Vaccine Candidate at IDWeek(TM) 2024
2024-10-10 16:07C:APLI0.025News ReleaseAppili acquiror Aditxt comments on acquisition
2024-10-10 16:02C:APLI0.025News ReleaseAppili corrects share acquisition price